A Study of MK-8189 Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: [14C]MK-8189

Study type: Interventional

Funder types: Industry

Identifiers

NCT06626464

MK-8189-010 (Other Identifier)

8189-010

Details and patient eligibility

About

The purpose of this study is to learn what happens to MK-8189 in a healthy person's body over time.

Enrollment: 6 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Key inclusion criteria include but are not limited to the following:

• Is in good health based on medical history, physical examination, VS measurements, and ECGs performed before randomization.
• Has a BMI ≥19 and ≤32 kg/m2, inclusive, at screening

Exclusion criteria

The key exclusion criteria include but are not limited to the following:

• Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
• Has a history of cancer.

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

Carbon-14 radiolabeled [14C] MK-8189

Experimental group

Description:

Participants receive a dose of 4.5-mg immediate release (IR) (\~ 50 μCi) orally on Day 1.

Treatment:

Drug: [14C]MK-8189